




RealRate

PHARMACEUTICAL 2021

Hepion Pharmaceuticals Inc
Rank 125 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Hepion Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 329%, being 72% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	42,634
Cost of Goods Sold	0
Intangible Assets	1,871
Liabilities, Current	4,662
Liabilities, Non-Current	296
Other Assets	4,040
Other Compr. Net Income	0
Other Expenses	62
Other Liabilities	3,167
Other Net Income	-146
Other Revenues	0
Property and Equipment	100
Research and Development	11,997
Selling, General and Administrative Expense	8,149

Output Variable	Value in 1000 USD
Assets	48,645
Liabilities	8,125
Expenses	20,208
Revenues	0
Stockholders Equity	40,520
Net Income	-20,354
Comprehensive Net Income	-20,354
BaseVar	38,562
ECR before Limited Liability	239%
Economic Capital Ratio	329%